Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company focused on people affected by kidney disease, announced on October 6, 2026 its upcoming presentations at the…
With an oncology program entering a registrational study and positive data from an oral obesity candidate, Corbus heads into the fourth quarter with two clinical…
September 30, 2026
Blood Cancer Awareness Month: The Next Wave of Treatments Is Moving Deeper Into the Biology of Disease
From protein degradation and menin inhibition to targeted radiopharmaceuticals and off-the-shelf cell treatments, companies are testing new ways to treat blood cancers and overcome resistance….
September 29, 2026
Invivyd’s VYD2311 Meets LIBERTY Phase 3 Safety Endpoints Against an mRNA COVID-19 Vaccine
Invivyd, Inc. (NASDAQ: IVVD), the New Haven, Connecticut developer of antibodies against viral infectious diseases, announced on September 29, 2026 topline results from LIBERTY, a…
Novo Nordisk (NVO) laid out its long-term growth ambitions at a capital markets day in London on Monday, and shareholders responded by marking the stock…
September 02, 2026
Scholar Rock Wins FDA Fast Track for FSHD Program as Patient Dosing Begins, With a Bigger SMA Decision Weeks Away
Scholar Rock, Inc. (NASDAQ: SRRK), a biopharmaceutical company applying its myostatin biology platform to rare neuromuscular diseases, announced on September 2, 2026 that the FDA…
August 17, 2026
Ocular Therapeutix Rises After EyePoint’s Wet AMD Trial Miss Reshapes Competitive Landscape
Key Points EyePoint’s DURAVYU did not meet LUGANO’s primary endpoint of change from baseline in best-corrected visual acuity compared with aflibercept in the full patient…